Unveiling chemotherapy-induced immune landscape remodeling and metabolic reprogramming in lung adenocarcinoma by scRNA-sequencing

• Published in: eLife 2024-12, Vol.13
• Main Authors: Huang, Yiwei, Wu, Gujie, Bi, Guoshu, Cheng, Lin, Liang, Jiaqi, Li, Ming, Zhang, Huan, Shan, Guangyao, Hu, Zhengyang, Chen, Zhencong, Lin, Zongwu, Jiang, Wei, Wang, Qun, Xi, Junjie, Yin, Shanye, Zhan, Cheng
• Format: Article
• Language: English
• Subjects: Adenocarcinoma; Adenocarcinoma of Lung - drug therapy; Adenocarcinoma of Lung - genetics; Adenocarcinoma of Lung - immunology; Adenocarcinoma of Lung - metabolism; Adenocarcinoma of Lung - pathology; Adjuvant treatment; Animals; Antineoplastic Agents - pharmacology; B cells; Cancer; Cell Line, Tumor; Drug resistance; Female; Health aspects; Humans; Immunotherapy; lung adenocarcinoma; Lung Neoplasms - drug therapy; Lung Neoplasms - genetics; Lung Neoplasms - immunology; Macrophages; Macrophages - immunology; Macrophages - metabolism; Male; Metabolic Reprogramming; Mice; neoadjuvant chemotherapy; Neoadjuvant Therapy - methods; Pemetrexed; phenotype atlas; T cells; Tumor Microenvironment
• ISSN: 2050-084X; 2050-084X
• DOI: 10.7554/eLife.95988

Chemotherapy is widely used to treat lung adenocarcinoma (LUAD) patients comprehensively. Considering the limitations of chemotherapy due to drug resistance and other issues, it is crucial to explore the impact of chemotherapy and immunotherapy on these aspects. In this study, tumor samples from nine LUAD patients, of which four only received surgery and five received neoadjuvant chemotherapy, were subjected to scRNA-seq analysis. In vitro and in vivo assays, including flow cytometry, immunofluorescence, Seahorse assay, and tumor xenograft models, were carried out to validate our findings. A total of 83,622 cells were enrolled for subsequent analyses. The composition of cell types exhibited high heterogeneity across different groups. Functional enrichment analysis revealed that chemotherapy drove significant metabolic reprogramming in tumor cells and macrophages. We identified two subtypes of macrophages: Anti-mac cells (CD45+CD11b+CD86+) and Pro-mac cells (CD45+CD11b+ARG +) and sorted them by flow cytometry. The proportion of Pro-mac cells in LUAD tissues increased significantly after neoadjuvant chemotherapy. Pro-mac cells promote tumor growth and angiogenesis and also suppress tumor immunity. Moreover, by analyzing the remodeling of T and B cells induced by neoadjuvant therapy, we noted that chemotherapy ignited a relatively more robust immune cytotoxic response toward tumor cells. Our study demonstrates that chemotherapy induces metabolic reprogramming within the tumor microenvironment of LUAD, particularly affecting the function and composition of immune cells such as macrophages and T cells. We believe our findings will offer insight into the mechanisms of drug resistance and provide novel therapeutic targets for LUAD in the future.